Kubota Pharmaceutical Holdings Co Ltd - ESG Rating & Company Profile powered by AI
This assessment of Kubota Pharmaceutical Holdings Co Ltd is assembled by All Street Sevva using advanced machine learning. Scroll down to the bottom of the page for potential risks for Kubota Pharmaceutical Holdings Co Ltd based on sector, geography and marketcap. The SDG score for Kubota Pharmaceutical Holdings Co Ltd represents the company's reporting of the United Nations SDGs.
Kubota Pharmaceutical Holdings Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.7, social score of 1.6 and governance score of 4.0.
2.8
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1353 | Vera Therapeutics Inc | 2.9 | Medium |
1353 | Veracyte Inc | 2.9 | Medium |
1393 | Kubota Pharmaceutical Holdings Co Ltd | 2.8 | Medium |
1393 | Bioventix PLC | 2.8 | Medium |
1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Kubota Pharmaceutical Holdings Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Kubota Pharmaceutical Holdings Co Ltd disclose current and historical energy intensity?
Does Kubota Pharmaceutical Holdings Co Ltd report the average age of the workforce?
Does Kubota Pharmaceutical Holdings Co Ltd reference operational or capital allocation in relation to climate change?
Does Kubota Pharmaceutical Holdings Co Ltd disclose its ethnicity pay gap?
Does Kubota Pharmaceutical Holdings Co Ltd disclose cybersecurity risks?
Does Kubota Pharmaceutical Holdings Co Ltd offer flexible work?
Does Kubota Pharmaceutical Holdings Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Kubota Pharmaceutical Holdings Co Ltd disclose the number of employees in R&D functions?
Does Kubota Pharmaceutical Holdings Co Ltd conduct supply chain audits?
Does Kubota Pharmaceutical Holdings Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Kubota Pharmaceutical Holdings Co Ltd conduct 360 degree staff reviews?
Does Kubota Pharmaceutical Holdings Co Ltd disclose the individual responsible for D&I?
Does Kubota Pharmaceutical Holdings Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Kubota Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 2 emissions?
Does Kubota Pharmaceutical Holdings Co Ltd disclose water use targets?
Does Kubota Pharmaceutical Holdings Co Ltd have careers partnerships with academic institutions?
Did Kubota Pharmaceutical Holdings Co Ltd have a product recall in the last two years?
Does Kubota Pharmaceutical Holdings Co Ltd disclose incidents of discrimination?
Does Kubota Pharmaceutical Holdings Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Kubota Pharmaceutical Holdings Co Ltd issued a profit warning in the past 24 months?
Does Kubota Pharmaceutical Holdings Co Ltd disclose parental leave metrics?
Does Kubota Pharmaceutical Holdings Co Ltd disclose climate scenario or pathway analysis?
Does Kubota Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Kubota Pharmaceutical Holdings Co Ltd disclose the pay ratio of women to men?
Does Kubota Pharmaceutical Holdings Co Ltd support suppliers with sustainability related research and development?
Does Kubota Pharmaceutical Holdings Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Kubota Pharmaceutical Holdings Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Kubota Pharmaceutical Holdings Co Ltd involved in embryonic stem cell research?
Does Kubota Pharmaceutical Holdings Co Ltd disclose GHG and Air Emissions intensity?
Does Kubota Pharmaceutical Holdings Co Ltd disclose its waste policy?
Does Kubota Pharmaceutical Holdings Co Ltd report according to TCFD requirements?
Does Kubota Pharmaceutical Holdings Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Kubota Pharmaceutical Holdings Co Ltd disclose energy use targets?
Does Kubota Pharmaceutical Holdings Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Kubota Pharmaceutical Holdings Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Kubota Pharmaceutical Holdings Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.